CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
- Written by PR Newswire Asia - Asian Spectator
![]() | ![]() |
European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN)
Decision follows positive recommendation from Committee for Medicinal Products for Human Use (CHMP) from February 2025
EU approval is based on the complete data set from the phase-III...